drugset / Trial / NCT04512430
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, non-randomised, phase II, multi-centre clinical trial 26 patients will be enrolled in this trial to evaluate the major pathologic response in patients with neoadjuvant treatment with Carboplatin Pemetrexed Bevacizumab plus Atezolizumab in patients with non-small cell lung carcinoma locally advanced mutated in EGFR
Timeline
- Start
- 2020-12-02
- Primary completion
- 2024-07-19
- Completion
- 2024-07-19
Outcome
Outcome not reported
Stopped (Enrollment): “Low recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |